Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026371 · ClinicalTrials.gov registry record · Phase 2
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Acute-graft-versus-host Disease, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 1
- Study location
NCT06026371: Active Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Acute-graft-versus-host Disease, sponsored by Fred Hutchinson Cancer Center.
NCT06026371 is a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Acute-graft-versus-host Disease that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 138 participants, below the 481-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06026371, a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Acute-graft-versus-host Disease, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving processed fecal material orally after allogeneic HCT in order to establish a healthy gut microbiota. Gut microbiota undergoes major alterations during allogeneic HCT because of antibiotic exposures, nutritional changes, and chemotherapy administration. Establishing a healthy gut microbiota via fecal transplantation may help prevent acute graft versus host disease in patients undergoing allogeneic HCT.
Primary Outcome
Based on International Blood and Marrow Transplantation Research (IBMTR) criteria and measured as a probability
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fecal Microbiota Transplantation Capsule
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What the registry record for NCT06026371 still lists
NCT06026371 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06026371 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06026371 about?
NCT06026371 is a clinical study titled "Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation". This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving ...
What is the current status of trial NCT06026371?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2023-12-12. Estimated completion is 2027-03-31.
What conditions does trial NCT06026371 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Acute-graft-versus-host Disease.
What interventions are being tested in trial NCT06026371?
The interventions under investigation include: Placebo (DRUG), Fecal Microbiota Transplantation Capsule (DRUG).
Who is sponsoring clinical trial NCT06026371?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06026371 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphatic System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06026371's enrollment target sits among peer trials
138 21st of 62 higher than 42 of 62 other Hematopoietic and Lymphatic System Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphatic System Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
RECRUITING · Phase 2
-
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
RECRUITING · Phase 2
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI